Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.
News|Articles|September 18, 2026
FAQ: What retina specialists need to know about the MOGENRY (MCO-010) BLA acceptance
The FDA has accepted Nanoscope's BLA for sonpiretigene isteparvovec in retinitis pigmentosa, backed by RESTORE and REMAIN trial data.
Advertisement
Advertisement
The US Food and Drug Administration has
Related to this article
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.
As with so many diseases, lung cancer manifests in men and women differently in type, symptoms, and prognosis.
4DMT's 4D-150 gene therapy enters phase 3 4SIGHT trial in DME; 2-year SPECTRA data show +10.8-letter BCVA gain in 9 patients.
At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border advancement pace and a location-weighted GA severity score.
A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.
Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.
Advertisement
Advertisement